Provenge and Clinical Outcomes by Baseline PSA Level

Provenge (Sipuleucel-T) is the first FDA approved cancer vaccine and it is still the only immune therapy approved for Prostate Cancer. In a post-hoc analysis it was demonstrated that those men who have lower PSA scores had a superior overall survival. The analysis also showed that men who had Provenge treatment have a lower risk of cardiovascular events.

PSA Doubling Time And Proximal PSA Predict Metastasis-Free Survival In Men With Biochemically Recurrent Prostate Cancer After A Radical Prostatectomy

PSA doubling time and the proximal PSA value are excellent predictors of the timing to the formation of metastatic prostate cancer in men who experience a biochemical recurrence (PSA only after surgery).